A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.